knowledge -WSS

knowledge

author：focus 2025-09-27 23:03:47 - browse：4

Kidney transplants are the most common organ transplant procedure in the U.S., with 25,000 taking place in 2022. But for patients who receive new kidneys, the transplant is often followed by severe lifelong challenges, many of which are linked to the immunosuppression drug regimen required after surgery to ensure the body does not reject the new organ. These treatments have side effects and toxicities that impact patients’ long-term health, and even survival, leading to a transplant failure rate of 30-50% at the 10-year mark.

Now a new trial sponsored by Medeor Therapeutics, the results of which were presented Thursday at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting, offers hope that stem cell therapy may help patients discontinue their immunosuppressant regime within a year of the transplant.

“The ability to get a transplant without being on lifelong immunosuppression is kind of a dream in transplant, so I can see why this would generate a lot of excitement,” said Sommer Gentry, a professor of surgery at New York University, who was not involved in the study and was not at the actual presentation, but reviewed the trial’s presentation slides.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Congress considering partial increase for doctor pay in Medicare

knowledge

WSS

Congress might make insulin pumps more accessible to the blind

Why don't Americans have at

Congress considering partial increase for doctor pay in Medicare

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

The a glaring gap in research on serious mental illness and primary care

AMAs digital advisors table RPM coding reform proposal, again

focus

knowledge

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medicare slashes safety net hospital payments by nearly $1 billion

BioMarin wins approval for gene therapy to treat hemophilia A

Bernie Sanders gets little from pharma CEOs on drug prices

Moonlake's readout produced a cash windfall. Risks remain

Tome Biosciences co

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Congress might make insulin pumps more accessible to the blind

Medicare proposal to cover medical devices draws a mixed reaction

Study gives hint on South Asians’ higher risk of cardiovascular disease

entertainment

The cancer stories no one wants to hear

The cancer stories no one wants to hear

Congress considering partial increase for doctor pay in Medicare

Group behind ProMed defends move to subscription

Congress might make insulin pumps more accessible to the blind

H.R. 3 is the wrong path to lower drug costs

focus

knowledge

knowledge

hotspot